TROP2-Directed Antibody–Drug Conjugates in Non-Small-Cell Lung Cancer: Current Use in Clinical Practice and Future Directions

In this episode, experts discuss the available efficacy and safety evidence along with their experiences with and strategies for integrating TROP2-directed antibody-drug conjugates into the management of patients with advanced NSCLC, with an emphasis on EGFR-mutant disease and a look at future therapeutic directions on the horizon.